Generalized anxiety disorder: acute and chronic treatment (Q34353112)

1 August 2017

1 reference

title

Generalized anxiety disorder: acute and chronic treatment (English)

1 reference

generalized anxiety disorder

1 August 2017

main subject

1 reference

2

Olga Brawman-Mintzer

1 reference

1 August 2017

Moira A Rynn

1

1 reference

1 August 2017

publication date

1 October 2004

1 reference

1 August 2017

1 reference

1 August 2017

volume

9

1 reference

1 August 2017

issue

10

1 reference

1 August 2017

page(s)

716-723

1 reference

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Treatment of generalised anxiety disorder with a short course of psychological therapy, combined with buspirone or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Clinical aspects of chronic use of alprazolam and lorazepam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Neurobiologic basis of anxiety and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Side effects of low dose neuroleptics and their impact on clinical outcome in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Drug therapy. Current status of benzodiazepines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Drug therapy. Current status of benzodiazepines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Factors predicting the clinical course of generalised anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Physical illness as an outcome of chronic anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Efficacy of sertraline in a 12-week trial for generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Guidelines for the rational use of benzodiazepines. When and what to use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

Group cognitive-behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Phenomenology and course of generalised anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

The nature and duration of treatment for GAD.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Potentiation of 5-HT neurotransmission by short-term lithium: in vivo electrophysiological studies

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

The economic burden of anxiety disorders in the 1990s.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Behavioral treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Biofeedback treatments of generalized anxiety disorder: preliminary results

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Characterizing generalized anxiety: temporal and symptomatic thresholds

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022367

7 January 2021

10.1017/S1092852900022367

Identifiers

DOI

1 reference

release_nhx7qaoeabfzzl6772j65i72k4

1 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nhx7qaoeabfzzl6772j65i72k4

24 November 2022

mapped directly with Wikidata item

1 reference